Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease

Kidney International

Volumn 77, Issue 1, 2010, Pages 23-28

  Barazzoni, Rocco ^a   Zhu, Xinxia ^b   Deboer, Mark ^b   Datta, Rakesh ^c   Culler, Michael D ^c   Zanetti, Michela ^a   Guarnieri, Gianfranco ^a   Marks, Daniel L ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c IPSEN   (France)

Author keywords

Insulin resistance; Mitochondria; Nutrition

Indexed keywords

GHRELIN; PROTEIN KINASE B; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BIOGENESIS; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL RAT; FOOD INTAKE; LIPID METABOLISM; MORBIDITY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

ANIMALS; EATING; GHRELIN; INSULIN; KIDNEY FAILURE, CHRONIC; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; NUTRITIONAL STATUS; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; TRIGLYCERIDES;

EID: 72949107126     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.411     Document Type: Article

References (36)

1. Conjard A, Ferrier B, Martin M et al. Effects of chronic renal failure on enzymes of energy metabolism in individual human muscle fibers. J Am Soc Nephrol 1995; 6: 68-74.
2. Adey D, Kumar R, McCarthy JT et al. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 2000; 278: E219-E225.
3. Bailey JL, Zheng B, Hu Z et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006; 17: 1388-1394.
4. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-152.
5. Petersen KF, Dufour S, Befroy D et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
6. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-520.
7. Shinohara K, Shoji T, Emoto M et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
8. Nakazato M, Murakami N, Date Y et al. A role of ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
9. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
10. Barazzoni R, Bosutti A, Stebel M et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-E235.
11. Barazzoni R, Zanetti M, Cattin MR et al. Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rat. Obesity 2007; 15: 2614-2623.
12. Poykko SM, Kellokoski E, Horkko S et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-2553.
13. Barazzoni R, Zanetti M, Ferreira C et al. Relationships between deacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3935-3940.
14. Barazzoni R, Zanetti M, Stulle M et al. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 2008; 27: 142-149.
15. DeBoer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007; 148: 3004-3012.
16. Deboer MD, Zhu X, Levasseur PR et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008; 149: 827-835.
17. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006; 116: 615-622.
18. Mak RH, Cheung W, Cone RD et al. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatr Nephrol 2005; 20: 427-431.
19. Vestergaard ET, Gormsen LC, Jessen N et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 2008; 57: 3205-3210.
20. Broglio F, Arvat E, Benso A et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-5086.
21. Heijboer AC, van den Hoek AM, Parlevliet ET et al. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia 2006; 49: 732-738.
22. Purnell JQ, Weigle DS, Breen P et al. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88: 5747-5752.
23. McLaughlin T, Abbasi F, Lamendola C et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin sensitive controls. J Clin Endocrinol Metab 2004; 89: 1630-1635.
24. Kopple JD, Berg R, Houser H et al. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int 1989; 27: S184-S194.
25. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-152.
26. van der Crabben SN, Allick G, Ackermans MT et al. Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate. J Clin Endocrinol Metab 2008; 93: 638-641.
27. Nakashima K, Yakabe Y, Yamazaki M et al. Effects of fasting and refeeding on expression of atrogin-1 and Akt/FOXO signaling pathway in skeletal muscle of chicks. Biosci Biotechnol Biochem 2006; 70: 2775-2778.
28. Valerio A, Cardile A, Cozzi V et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006; 116: 2791-2798.
29. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
30. Barazzoni R, Bernardi A, Biasia F et al. Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease-impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol 2007; 293: R47-R54.
31. Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
32. Cai D, Frantz JD, Tawa Jr NE et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-298.
33. Zhang L, Du J, Hu H et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20: 604-612.
34. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
35. Murata M, Okimura Y, Iida K et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277: 5667-5674.
36. Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.